David M. Spencer
Geen lopende functies
Loopbaan van David M. Spencer
Eerdere bekende functies van David M. Spencer
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 14-07-2004 | 01-03-2019 |
| Oprichter | 14-07-2004 | 01-03-2019 | |
| KIROMIC BIOPHARMA, INC. | Directeur/Bestuurslid | 01-10-2019 | - |
| Hoofd Techniek/Wetenschap/O&O | 01-10-2019 | - | |
| Baylor College of Medicine | Corporate Officer/Principal | - | - |
Opleiding van David M. Spencer
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Beurs
- Insiders
- David M. Spencer
- Ervaring
